

# Everolimus (RAD001, Afinitor®) and Cyclophosphamide in Castration and Docetaxel resistant Prostate Cancer, a proof of principle Phase II study.

Published: 29-10-2010

Last updated: 02-05-2024

The primary objective is to study whether treatment with the mTOR inhibitor Everolimus results in an objectable change in phosphorylation of the selected downstream effectors 4eBP1 and p70S6K in human prostate cancer biopsies. A secondary objective...

<b>Ethical review</b>	Not approved
<b>Status</b>	Will not start
<b>Health condition type</b>	Reproductive neoplasms male malignant and unspecified
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON35076

### Source

ToetsingOnline

### Brief title

Metronomic treatment of castration resistant prostate cancer

### Condition

- Reproductive neoplasms male malignant and unspecified

### Synonym

Cancer of the prostate, prostatic neoplasm.

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Nederlands Kanker Instituut

**Source(s) of monetary or material Support:** instituut zelf

## Intervention

**Keyword:** castration resistance, cyclophosphamide, Everolimus, metronomic therapy, mTOR inhibition, Prostate cancer, signal transduction

## Outcome measures

### Primary outcome

In order to investigate the mTOR inhibition in the prostate by Everolimus and the possible synergistic interaction with low dose, metronomic, oral Cyclophosphamide treatment, phosphorylation of 4eBP1 and p70S6K will be assessed in prostate biopsies of prostate cancer patients.

### Secondary outcome

PSA response

Toxicity of the combined Everolimus and Cyclophosphamide treatment

## Study description

### Background summary

progress has been made in the last decades in the treatment of other prevalent solid tumors, such as breast and colorectal cancer. New treatment modalities and new drug regimens have been developed which resulted in increased median survival and better quality of life of patients affected by these diseases. However, the prognosis of patients with prostate cancer, which is irresponsive to castration, is very poor and has not changed in recent years. There is an urgent need for new treatment modalities that will improve the quality of life and life span of prostate cancer patients.

### Study objective

The primary objective is to study whether treatment with the mTOR inhibitor Everolimus results in an objectable change in phosphorylation of the selected downstream effectors 4eBP1 and p70S6K in human prostate cancer biopsies.

A secondary objective is to study tolerability and PSA response of the combination of continuous low-dose cyclophosphamide and Everolimus.

## **Study design**

This is a phase II study.

Patients with a rising PSA under castrate serum testosterone levels and previously treated with Docetaxel might be eligible for this study. Baseline investigations will include prostate biopsies and blood analysis, physical examination, recording of medical history, concomitant drug use and ECOG performance status (Appendix 2). After 2 weeks of lead-in Everolimus treatment, prostate biopsies and blood analysis and physical examination will be performed and toxicity score, concomitant drug use and ECOG performance status will be recorded. Everolimus treatment will be combined with cyclophosphamide once daily 50 mg from week 3 on. Patients will visit their physician every 2 weeks during the first 8 weeks of treatment followed by every 4 weeks, for history taking, physical examination (including ECOG performance status), laboratory tests and recording of toxicity. In order to monitor for, subclinical, non-infectious pneumonitis, a Chest X-ray will be made every 8 weeks during treatment. Patients will continue this treatment until PSA progression, disease progression or > grade 3 toxicity.

## **Intervention**

Everolimus treatment will be prescribed at two dose levels. The first ten included patients will be treated at a dose of 5 mg once daily. In case of \* 20 % Grade 3 toxicity after 6 weeks of treatment (2 weeks Everolimus single agent and 4 weeks combined Everolimus and cyclophosphamide treatment), the Everolimus dose will be increased to 10 mg per day for the next 10 patients. Besides, prostate biopsies will be taken prior- and after four weeks of Everolimus alone treatment.

## **Study burden and risks**

Patients will visit their physician every two weeks during the first eight weeks and every four weeks thereafter. There will be more laboratory tests than there would be outside this study. There is a significant chance that patients will experience side effects of the treatment. In a pilot study to combination of Everolimus and Cyclophosphamide lymphopenia, neutropenia, thrombopenia, anaemia and fatigue were most frequently described. Besides, prostate biopsies will be taken prior- and after four weeks of Everolimus alone treatment. Some patients describe taking prostate biopsies as painful. Possible risks include bleeding or infection of the prostate.

Benefit for the patient might be a palliative effect of the treatment or complaints might be postponed.

## Contacts

### Public

Nederlands Kanker Instituut

Plesmanlaan 121  
1066 CX AMsterdam  
Nederland

### Scientific

Nederlands Kanker Instituut

Plesmanlaan 121  
1066 CX AMsterdam  
Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

- Prostate cancer diagnosis and a rising PSA under castrate serum testosterone levels (2 rises in a period of at least 3 months), PSA > 10ng/ml.
- At least one prior cycle of Docetaxel treatment.
- ECOG performance status 0-2.
- Locally accessible prostate cancer for TRUS-guided biopsies.
- Written informed consent.
- Laboratory requirements:
  - a) Hematology:
    - \* Hemoglobin > 5 mmol/L
    - \* Platelet count \* 100,000/\*L
    - \* No leucopenia
  - b) Hepatic function:

- \* AST and ALT \* 2.5 times upper limit of normal (ULN)
- \* Bilirubin \* 1.5 times ULN
- c) Renal function:
  - \* Calculated GFR (Cockcroft) \* 60 ml/min
  - \* PT/PTT normal (no anticoagulants)
- Fertile patients must use effective contraception during and for 6 months after completion of study therapy.

## Exclusion criteria

- Small cell pathology.
- Allergy to Everolimus or cyclophosphamide or components of Afinitor ® or Endoxan ®.
- Co-medication interfering with CYP3A4 activity.
- Gastrointestinal (GI) disease, condition, or symptoms that may significantly impair GI function and alter the absorption of Everolimus, including any of the following:
  - o Ulcerative disease
  - o Vomiting
  - o Diarrhea
  - o Malabsorption syndrome
- Other active malignancy or malignancy at \* 30% risk for relapse after completion of therapy, except nonmelanoma skin cancer .
- Recent (within 2 weeks) surgery.
- Uncontrolled concurrent illness including, but not limited to, any of the following:
  - o Ongoing or active infection (e.g., bacterial, viral or fungal)
  - o Severely impaired lung function
  - o Uncontrolled diabetes (fasting serum glucose > 1.5 times ULN)
  - o Liver disease (e.g., cirrhosis, chronic active hepatitis, or chronic persistent hepatitis)
  - o Symptomatic congestive heart failure
  - o Unstable angina pectoris
  - o Cardiac arrhythmia
- Lower urinary tract obstruction not treated with bladder catheterisation.

## Study design

### Design

Study phase: 2

Study type: Interventional

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

## Recruitment

NL	
Recruitment status:	Will not start
Enrollment:	20
Type:	Anticipated

## Medical products/devices used

Product type:	Medicine
Brand name:	Cyclophosphamide
Generic name:	Cyclophosphamide
Registration:	Yes - NL outside intended use
Product type:	Medicine
Brand name:	Everolimus (RAD001, Afinitor®)
Generic name:	Everolimus (RAD001, Afinitor®)
Registration:	Yes - NL outside intended use

## Ethics review

Approved WMO	
Date:	29-10-2010
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Not approved	
Date:	10-12-2010
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
EudraCT	EUCTR2010-018772-24-NL
CCMO	NL31523.031.10